Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
No clue what a Submillemeter Wave Quantized Space Therapy Chamber is but according to the filings:
I'm IMpatiently waiting LOL
Still patiently waiting here too. Lets go HY get on it!
They hit us with an outta nowhere filing with this tiny float we know what haps!)
It's not going to take much to move this one to dollar land with the small float.
Been holding this for a long time. Low float stock that could take off at anytime.
haha yeah bro - ain't no thang. This will move on air when the stars align! ;)
Then 100 shares to 0052 bid with the big spread lol
hilar..funny mofogamez
pfff
looking forward to this really catching real interest 1 day...soon would be great lol. We know it's paper thinny!
Some nice chirps today. See what coming days bring.
1 these days won't be fluke day of vol imo. Will see!
0023x023..someone scored few gifts on bid there
Someone was buying in and seems to want more. I am considering buying more. I think this will be an HR eventually.
sounds like big tingz on the horizon
Some NICE tidbits in the 10q out yest! Hmmmm
Since the beginning of 2019, Mr. Xu has led the core research and development team of Kangzi to develop and manufacture a new medical product, the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the “Chamber”). Utilizing submillimeter waves, the Chamber is a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber. We believe that exposure to an appropriate amount of submillimeter waves would accelerate the generation of a large number of cosmic ray muons inside the human body and that such cosmic ray muons could further facilitate cold nuclear fusion, which could reverse the cancer by converting selenium into nickel inside cells.(we know this is a MAJOR claim since Heyu RMed too and this could be the kicker! Never know!)
Our team consists of researchers who have years of extensive experience in medicine and physics. The lead scientist of the team, Mr. Xu, had extensive professional experience in the aforementioned fields and has served as the deputy chief engineer of the New Energy Base of the National Defense-Science and Technology Commission in 1995, the chairman and chief scientist of Shanghai Guangcon New Energy Technology Co., Ltd. from 2011 to 2019, and the director of Shanghai Hengbian New Energy Research Institute from 2003 to 2008. In 2012, Mr. Xu received the “Harmony-Person of the Year in China” award at the “2011 Harmony China Annual Summit” in Beijing. He was recognized as “Leaping China: One of the Most Influential People of the Year in 2011” by China International Economic and Technical Cooperation Promotion Association, China Elite Culture Promotion Association, and China Outstanding Chinese Merchants Association. Mr. Xu also received the “2013 China Economic Outstanding Contribution Award” from the Organizing Committee of Boau Forum on Asian SME Development.
Pursuant to the terms of the share transfer agreement entered into by JSEL and Kangzi on January 17, 2019, JSEL has the right to monitor and manage all aspects of operation of Kangzi, including its research and development activities relating to the Chamber. As the development of the Chamber enters its final stage, JSEL started accepting pre-orders for the Chamber in September 2019.
The outbreak of the novel coronavirus, commonly referred to as “COVID-19”, first found in mainland China, then in Asia and eventually throughout the world, has significantly affected business and manufacturing activities within China, including travel restrictions, widespread mandatory quarantines, and suspension of business activities within China. These measures have caused substantial disruptions to our business operations and most of our staff members were forced to work from home until March 1, 2020. Accordingly, our business, results of operations and financial condition were adversely affected. We suspended our business operation in early February 2020 due to government mandates. We partially recovered our business operation on February 17, 2020, and we fully resumed our business operations on March 1, 2020. As of the date of this report, Chinese industries have gradually resumed businesses as government officials started to ease the restrictive measures since April 2020. We have experienced significant growth in sales during the fiscal quarter ended June 30, 2020, as compared to that of the fiscal quarter ended March 31, 2020. Our management believes that our revenues will keep growing in the upcoming fiscal quarters.
On March 17, 2020, we entered into a business service cooperation agreement with Xiamen Qingda Intelligent Technology Co., Ltd., a wholly-owned subsidiary of Cross-strait Tsinghua Research Institute, pursuant to which we agreed to jointly improve the plant based disinfectant spray for treating skin infections and disinfecting wounds. The term of such agreement is three years, and can be renewed upon mutual agreement of both parties. The original plant based disinfectant spray was developed and owned by the Company, while the improved product shall be owned by both the Company and the Cross-strait Tsinghua Research Institute. The Cross-strait Tsinghua Research Institute will receive 2% of gross proceeds from the sales of such improved product. By the end of April 2020, we have had generated revenues of approximately $5,693.25 through sales of the improved product.
I'm holding on tight! Def something up here IMO $HYBT
lolz berry juice.. maybe it cures da rona
Ever truly catches on who knows where could top out lol.
Maybe they get into PPE or vacs or somethin lol..never know
they sold berry juice to make few bux so they got that hustla mindset lol.
$1 pre news would be great lol
Creepin on the COME UP!
Something going on here. I wouldn't be selling now.
I would bet the 100k @ 031 doesn't fill
I didn't think that 100k @ 03 would get filled. Someone got a gift.
It looks like GO TIME imo
$SSFT
NICE support outta nowhere! 200k 600ker! HMMMMMM!
For some reason I feel like this could be a situation where one day we wake up and this thing is at a $1 then trading on NYSE.
Wasn't it these guys that were looking to list direct to NYSE years ago? Perhaps this is the route they decided to use instead. RTO/RM's are gaining popularity with bigger companies.
Waiting game for the last while perhaps because they are trying to acquire the remainder of the float left after takeover, RS/FS... will be interesting to see what happens!
All just my thoughts / opinion.
GLTA
Can't wait to see what happens with this lotto. 1000%+ or bust! Weeeee lol $HYBT
GM TT and all! See what haps this week here..
any real upside vol and oh man!) Lets see it!
.50 would be amazing and very possible w what I read about HYBT
See yall next week!
SGO HEYU!!!
Ya know lol.
Sooo thin! Never know with these China RM types..
from zeros to HEROS like WOOPS outta nowhere. See what next week brings!) Sure nice to see the increase in the acct too..lets get it mang! See ya Monday!
This could creep up to .50+ on air IMO
Yep .025 decided to cancel once he saw the interest I'm guessing
Peanut float. There's a 10k ask hit 0448 nice! Bids rising. Hmmm I likes!
Man o man some real vol and action here welp....from lame to FAME woop!) QUICK!
WOW lookin NICE outta nowhere TT!
Bene all over the map today here now just seeing the HUGE UTs and support showing! Come on Heyu lets do it this time!!
HYBT looks like it is ready for a large move. Big bids lining up, sellers are moving out of the way.
It looks like either 8/12 or 8/14 a 10Q is posted. Maybe something good is coming
It's not going to take much. The float is very small.
This went to .035 on huge volume in May. MArket makers seem to be abandoning the ask and we are seeing a little bidding today. Hopefully May’s actively was from smart investors getting in early. Would love to see this one make another big run.
Just a matter of time on this one. Super low float. Can for big and fast.
Some action today. See if continues manana.
I'm holding and waiting
I agree. Not much of a float so it could run big and fast.
Feels like something is about to happen fairly soon!
GM TT and all! Interesting box still here. Lets see what haps here today.
The activation last week and continuation of bids and built box is odd to say the least. Lets hope it is a start of something very nice here man! Cheers!
Something going on here 600k on the bid
Yah will see what haps..
still bidders wanting stock hmm. What happened was interesting to say the least and now supported 3x higher than before it started lol..so will see how goes here. Hopefully not just a flash in the pan. Someone bought 340k twice in the 3s though too so?! Will see.
Refer to my last post..from the latest 10k..maybe they are about to do something. Again will see lol. Least we have a TIGHT float and is fully reporting.
TA update float still same..10,734,200
Authorized: 2,000,000,000
Outstanding: 1,032,466,000
Restricted: 1,021,731,800
Free Trading: 10,734,200
(which is right from my old math pre 100 for 1 FS was around 100k free trade with about half that in play. So yah good stuff in that regard imo.)
Thank you,
Amy Merrill
Standard Registrar and Transfer Company
So will see what comes of this recent vol/activity with no chatter or news yet. Hopefully company steps up what they talked about in recent filings..(from March 10k)..
New Business Initiative – Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber Project
Since the beginning of 2019, Mr. Xu has led the core research and development team of Kangzi to develop and manufacture a new medical product, the Submillimeter Wave (Terahertz) Quantized Space Therapy Chamber (the “Chamber”). Utilizing submillimeter waves, the Chamber is a medical equipment designed to treat cancer through cold nuclear fusion caused by cosmic ray muons in an enclosed chamber. Specifically, we believe that exposure to an appropriate amount of submillimeter waves could accelerate the generation of a large number of cosmic ray muons inside the human body and that such cosmic ray muons could further facilitate cold nuclear fusion, which could reverse the cancering process through which selenium is converted into nickel inside cells.
The team consists of researchers whom have extensive experience in medicine and physics. The lead scientist of the team, Mr. Xu, had served as the deputy chief engineer of the New Energy Base of the National Defense-Science and Technology Commission in 1995, as the chairman and chief scientist of Shanghai Guangcon New Energy Technology Co., Ltd. from 2011 to 2019, and the director of Shanghai Hengbian New Energy Research Institute from 2003 to 2008. In 2012, Mr. Xu was rewarded the “Harmony-Person of the Year in China” at the “2011 Harmony China Annual Summit” in Beijing and recognized as “Leaping China: One of the Most Influential People of the Year in 2011” by China International Economic and Technical Cooperation Promotion Association, China Elite Culture Promotion Association, and China Outstanding Chinese Merchants Association. In 2013, the Organizing Committee of Boau Forum on Asian SME Development awarded Mr. Xu “2013 China Economic Outstanding Contribution Award.”
2
Pursuant to the terms of the Share Transfer Agreement entered into by JSEL and Kangzi on January 17, 2019, JSEL has the right to monitor and manage all aspects of operation of Kangzi, including its research and development activities relating to the Chamber. As the development of the Chamber enters its final stage at Kangzi, JSEL started accepting pre-orders for the Chamber in September. Subsequently, on October 15 2019, JSEL entered into a clinical cooperation agreement (the “Clinical Cooperation Agreement”) with Shenzhen Saikun Biotechnology Co., Ltd. (“Saikun”). Pursuant to the Clinical Cooperation Agreement, Saikun agreed to pay JSEL 5.5 million RMB as the total preordering payment. 1.5 million RMB and 1.5 million RMB were delivered to JSEL respectively on September 7 and September 27, 2019. The parties are working on the timing for payment of the remaining 2.5 million RMB due under the Clinical Cooperation Agreement. In exchange, JSEL is obligated to purchase all the components of a Chamber from Kangzi, fully assemble it, and conduct a clinical trial with Saikun, third-party hospital partners, and patients using the Chamber. Specifically, after receiving the full amount of payment from Saikun, JSEL shall transport the Chamber to its preferred location, properly install it, and conduct a clinical trial that lasts at least one month. During the clinical trial, JSEL shall provide training sessions regarding the proper operation of the Chamber to Saikun’s employees. Both Saikun and JSEL are obligated to find third-party hospitals whom will agree to act as partners to co-host the clinical trial and patients whom will be voluntarily willing to undergo treatment provided by the Chamber. While Saikun is responsible for various expenses related to the clinical trial, JSEL is responsible for communicating with patients receiving treatment and other patient-related administrative matters. When JSEL determines that Saikun is capable of properly operating the Chamber and managing activities related to the Chamber, Saikun may request JSEL to move the Chamber to a location designated by Saikun and reinstall it. Furthermore, upon the successful completion of the clinical trial, JSEL shall provide Saikun governmental permits necessary for the operation of the Chamber, and Saikun shall operate the Chamber and provide related services to patients under the supervision of JSEL. In addition, JSEL shall transfer the right of using the Chamber and any beneficiary right affiliated to using the Chamber to Saikun upon receiving the full amount of payment from Saikun. JSEL, nevertheless, owns all the intellectual property rights affiliated with the Chamber. If the two parties decide to terminate the Clinical Cooperation Agreement prior to the expiration of the term, Saikun’s right of using the Chamber during the term is still effective as long as its use of the Chamber does not infringe any of JSEL’s intellectual property rights affiliated with the Chamber. The two parties agreed that the term of the Clinical Cooperation Agreement would not end until Kangzi successfully obtains permits issued by relevant government entities supervising development and sale of medical equipment.
To prepare for the mass production of Chambers, Kangzi is conducting clinical experiments to make further improvements on Chamber and adjusting features of the mass-production mold for Chamber. Kangzi is also in the process of obtaining official governmental permits from relevant government authorities to produce and sell Chambers on a national scale. As its long-term business strategy, Kangzi focuses on researching, developing, and manufacturing high-technology medical equipment while targeting both individual and institutional customers. It plans to massively manufacture Chambers in small and medium sizes, establish operation centers to sell Chambers in various cities across China, and initiate advertising and marketing campaigns on different media platforms. Kangzi will also monetize on services provided to customers who use Chambers and other medical products.
In addition to business activities related to Chamber, the Company will commit to the research, development, manufacturing, and sale of healthcare equipment and various health products containing natural plants, including cosmetics, nutritional supplements, and drugs. In the near future, the Company aims to standardize and internationalize the production and sale of healthcare equipment and health products, while increasing its brand awareness in the healthcare and consumer-product markets.
3
Corporate Structure
Currently, the Company owns 100% of HP TECHNOLOGY LIMITED, a British Virgin Islands business company incorporated on September 20, 2018. HP TECHNOLOGY LIMITED owns 100% of Heyu Healthcare Technology Limited, a Hong Kong company incorporated on March 29, 2018. Heyu Healthcare Technology Limited owns 100% of JSEL, which in turn holds 60% of Kangzi. The following diagram sets forth the structure of the Company as of the date of this Current Report:
Looks like Friday was some sort of flash in the pan. Nothing happening today.
Followers
|
90
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
4143
|
Created
|
01/30/06
|
Type
|
Free
|
Moderators |
REVERSE MERGER TO HYBT!
-Split and control block of 10mil issued to the 322,000 OS prior to Name and Ticker change to HYBT.
Of the 322,000 over 200,000 is another control block initially issued to old shell buyer CEO Masters.
-Fully reporting SEC filer
-True float right now pre FS around 30-50k based on the 10mil control block issued into RM plus the other control block prior old shell ceo owned around 200k. Leaves around 100k with true free trading float a fraction of that as stated.
-Now a 100 for 1 FS filing out 8k Sept 14th 2018
*MORE INFO AND UPDATES TO COME!*
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |